Neoadjuvant Therapy with Weekly Nanoparticle Albumin‐Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011‐02), a Multicenter, Non‐Randomized, Phase II Trial, with a Companion Biomarker Analysis

BACKGROUND. Nanoparticle albumin‐bound paclitaxel (nab‐Paclitaxel) is an alternative to standard taxanes for breast cancer (BC) treatment. We evaluated nab‐Paclitaxel efficacy as neoadjuvant treatment for early estrogen receptor‐positive (ER+), human epidermal growth factor receptor 2‐negative (HER2...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncologist
Autori principali: Martín, Miguel, Chacón, José I., Antón, Antonio, Plazaola, Arrate, García‐Martínez, Elena, Seguí, Miguel A., Sánchez‐Rovira, Pedro, Palacios, José, Calvo, Lourdes, Esteban, Carmen, Espinosa, Enrique, Barnadas, Agusti, Batista, Norberto, Guerrero, Angel, Muñoz, Montserrat, Romio, Estefania, Rodríguez‐Martín, César, Caballero, Rosalía, Casas, María I., Rojo, Federico, Carrasco, Eva, Antolín, Silvia
Natura: Artigo
Lingua:Inglês
Pubblicazione: AlphaMed Press 2017
Soggetti:
Breast Cancer
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5679821/
https://ncbi.nlm.nih.gov/pubmed/28701571
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0052
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi